Lana Pine

Patients with RA reported worse outcomes for all PROMs compared with CSA or UA.

Among the nurse-led cohort, 83% of patients with gout achieved target p-urate levels and 98% continued treatment with urate lowering therapy.

The incidence of gout was 2.9 per 1000 patient-years, which dropped by 30% at the beginning of the COVID-19 pandemic.

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population.

Strategies designed to promote medication adherence were found in only 1 out of 3 websites.

Patients receiving abatacept experienced smaller increases in mean IMT, max IMT, and plaque score compared with the csDMARD cohorts.

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

After being prescribed another urate lowering therapy for ≥ 30 days, only 51.0% of patients were able to achieve SU < 6 mg/dL.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.

Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.

NSAID use decreased the odds of a cardiovascular event by 12% in patients with gout.

Participants described the intervention as complete and coherent and would recommend this intervention to other patients.

EULAR’s fibromyalgia guidelines provide comprehensive recommendations for managing active fibromyalgia to assist clinicians in making informed decisions. Test your knowledge with this quiz.

S Louis Bridges Jr, MD, PhD, explores the role of artificial intelligence in managing rheumatoid arthritis.

Benjamin Smith, DMSc, PA-C, discusses integrative rheumatoid arthritis treatment guidelines.

Jinny Tavee, MD, explains the potential neurological complications of sarcoidosis, an autoimmune disease that affects multiple systems.

Tracy Frech, MD, MSCI, explains what rheumatologists need to know about preventing and management digital ischemia.

Without controlling for the severity of symptoms, patients with either fibromyalgia or RA performed worse when compared with controls in terms of cognitive domains including verbal memory, visual memory, and strategic planning.

Alkaline water significantly reduced VAS pain scores among patients with gout.

Five barriers to adopting TNF therapeutic drug monitoring emerged among a cohort of experienced rheumatologists.

For those with a family history of gout, the proportion of grade ≥ 2 left ventricular diastolic insufficiency was markedly higher compared with patients without family history.

The median survival for triple therapy was longer compared with double therapy (15.1 months vs 9.6 months).

Obesity was linked to a lower likelihood of obtaining response to treatment during the 48-week follow-up period.

Patients with gout who had poor health literacy were more likely to experience ≥ 2 flares within the previous 12 months.

Philip J Mease, MD, highlights recent data comparing the safety and efficacy of bimekizumab with other DMARDs for the treatment of PsA.

Katie Abouzahr, MD, explains the transformative potential of nipocalimab for the treatment of patients with autoantibody-driven conditions.

Patients with higher disease activity reported the highest perceived consequence of disease.

Manuel Litchman, MD, further discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.